Antifungal Treatment for Cladosporium Species
For Cladosporium species infections, voriconazole or itraconazole are the preferred antifungal agents, with azoles demonstrating superior activity compared to amphotericin B or echinocandins.
Primary Treatment Recommendations
Voriconazole is the first-line agent for Cladosporium infections based on the most recent clinical evidence and susceptibility data 1, 2. The recommended dosing is:
- Loading dose: 400 mg (6 mg/kg) IV twice daily for 2 doses
- Maintenance: 200-300 mg (3-4 mg/kg) IV or oral twice daily
Itraconazole serves as an effective alternative 3, 1:
- 200 mg oral solution twice daily
- Serum levels should be monitored after 2 weeks to ensure adequate drug exposure
Susceptibility Profile and Drug Selection
Recent susceptibility testing of 92 clinical Cladosporium isolates from the United States reveals critical patterns 1:
- Azoles (triazoles): MIC range 0.12-2 μg/ml - demonstrating excellent activity
- Amphotericin B: MIC 4 μg/ml - significantly less active than azoles
- Echinocandins: MIC 2-8 μg/ml - poor activity, not recommended
- Terbinafine: Shows comparable activity to azoles in vitro 3
The most recent data from 2023 confirms triazoles remain more active against Cladosporium species compared to polyenes or echinocandins 2.
Alternative and Adjunctive Options
Terbinafine may be considered when azoles cannot be used, as in vitro studies demonstrate comparable fungicidal activity to itraconazole and amphotericin B against Cladosporium species 3.
Amphotericin B (lipid formulation 3-5 mg/kg daily or deoxycholate 0.7-1.0 mg/kg daily) can be used if azoles are contraindicated, though it is less preferred due to inferior activity and higher toxicity 4, 5.
5-Fluorocytosine (5-FC) showed therapeutic benefit in experimental Cladosporium infections and may be considered as combination therapy in severe cases 6.
Critical Clinical Considerations
Drug-Resistant Isolates
A 2024 case report documented multidrug-resistant Cladosporium keratitis (including voriconazole resistance) successfully treated with topical povidone-iodine 5% 7. This highlights the importance of:
- Obtaining antifungal susceptibility testing when possible
- Considering alternative agents if clinical response is inadequate
- For ocular infections specifically, topical povidone-iodine may be effective
Site-Specific Management
- Respiratory tract infections (54.5% of cases): Systemic azole therapy required 1
- Superficial infections (28.4%): May respond to topical or oral azoles
- Deep tissue/fluid infections (14.7%): Require prolonged systemic therapy, often with surgical debridement 1
Duration of Therapy
While guidelines don't specify exact duration for Cladosporium, treatment should continue until:
- Complete resolution of clinical symptoms
- Radiographic improvement (for pulmonary disease)
- Minimum 6-12 weeks for invasive disease (extrapolated from other dematiaceous fungi guidelines) 4, 5
Common Pitfalls to Avoid
Do not use echinocandins as monotherapy - they demonstrate poor activity (MIC 2-8 μg/ml) against Cladosporium 1, 2
Do not assume all "black molds" respond similarly - Cladosporium has distinct susceptibility patterns compared to Aspergillus or mucormycosis
Do not rely on phenotypic identification alone - molecular methods (ITS, LSU, ACT, TUB gene sequencing) are essential for accurate species identification 1, 2
Monitor itraconazole levels - variable bioavailability requires therapeutic drug monitoring to ensure adequate exposure 4, 8
Consider surgical intervention - for localized lesions, especially in immunocompromised patients, surgical debridement significantly improves outcomes 9